Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib

benzinga.com/news/health-care/25/06/45841878/analyst-says-newamsterdam-stock-has-over-100-upside-citing-90-success-probability-for-obicetrapi

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) on Monday released topline data from pre-specified Alzheimer’s Disease biomarker analyses in the Phase 3 BROADWAY clinical trial.
The study was primarily designed to evaluate the efficacy of obicetrapib in lowering low-density lipoprotein…

This story appeared on benzinga.com, 2025-06-09 16:23:57.
The Entire Business World on a Single Page. Free to Use →